Clinical trials: Covid19 Vaccination
Covid-19
Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020
Experimental Use of Convalescent Plasma of Passive Immunisation In Current COVID-19 Pandemic in Pakistan in 2020 Rationale \& Objective: This study would help to gather real-life setting clinical data in local population…
- Trial name
- NCT04352751
- Testing
- convalescent plasma
- Where
- Pakistan
- Volunteers
- 2,000 people, healthy volunteers welcome
- Sponsor
- Hilton Pharma
SARS CoV 2 Infection
A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults.
A phase IIb/III, open label, single arm, multi-centre, trial to assess the immunogenicity and safety of an additional dose vaccination with a recombinant protein RBD fusion heterodimer candidate (PHH-1V) against SARS-CoV-2, in…
- Trial name
- NCT05303402
- Testing
- PHH-1V
- Where
- 6 sites in Spain, Turkey (Türkiye)
- Volunteers
- 241 people
- Sponsor
- Hipra Scientific, S.L.U
COVID-19 Pneumonia, Coronavirus Infections
Clinical Trial on Sequential Immunization of Recombinant COVID-19 Vaccine (CHO Cells,NVSI-06-08) and Inactivated COVID-19 Vaccine (Vero Cells) in Population Aged 18 Years and Above
This is randomized, blinded and controlled design. Among the randomly selected subjects who have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell), based on a step-wise approach, the subjects will receive…
- Trial name
- NCT05069129
- Testing
- Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08), Inactivated COVID-19 vaccine (Vero cells), 3 doses Recombinant COVID-19 Vaccine (CHO cell，NVSI-06-08)
- Where
- United Arab Emirates
- Volunteers
- 1,848 people, healthy volunteers welcome
- Sponsor
- National Vaccine and Serum Institute, China
Coronavirus Disease (COVID-19)
Long-Term Follow-up Survey of COVID-19 Vaccine After Vaccination
This study is a long-term follow-up survey of Japanese people after their second vaccination with the Moderna COVID-19 vaccine. The study sponsor will not be involved in how the participants are treated but will provide…
- Trial name
- NCT04941144
- Testing
- COVID-19 Vaccine
- Where
- Japan
- Volunteers
- 8,538 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Covid19
Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults and Boost (VXA-CoV2-1.1-S) at 1 Year Post Initial Vaccination in Subset of Subjects
VXA-CoV2-1 is a non-replicating Ad5 vector adjuvanted oral tableted vaccine being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection.
- Trial name
- NCT04563702
- Testing
- VXA-CoV2-1
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Vaxart
COVID-19 Pandemic
The Immunogenicity and Safety of V-01-351/V-01D Bivalence Vaccine
It is a Single Arm, Open Label Clinical Study to Evaluate the Immunogenicity and Safety of Sequential Immunization of V-01-351/V-01D Bivalence Vaccine in Healthy Adults Aged 18 Years and Older After the Vaccination of 2 Doses of…
- Trial name
- Omicron (NCT05273528)
- Testing
- Recombinant SARS-CoV-2 Beta Variant Fusion Protein Vaccine/Recombinant SARS-CoV-2 Delta Variant Fusion Protein Vaccine
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Livzon Pharmaceutical Group Inc.
COVID-19
A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)
The Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell) developed by WestVac Biopharma Co., Ltd. is a monovalent modified vaccine designed against Omicron XBB.1.5.
- Trial name
- NCT06175494
- Testing
- Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell), Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
- Where
- China
- Volunteers
- 4,800 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
SARS-CoV-2
Post-Marketing Safety Study in Japan of Shock and Anaphylaxis After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in Persons in at High Risk of Severe COVID-19
The goal of this study is to confirm the onset status of hypersensitivity reactions including shock and anaphylaxis observed after vaccination with this drug in persons with underlying diseases who are considered to have a high…
- Trial name
- NCT05894499
- Where
- Japan
- Volunteers
- 13,309 people
- Sponsor
- ModernaTX, Inc.
Prevention of COVID-19
ZF2001 Booster Immunization Clinical Trials of 6 Months After the Completion of Basic Immunization
The purpose of this study is to evaluate the immunogenicity and safety of the recombinant novel coronavirus vaccine (CHO cells) after the booster immunization.
- Trial name
- NCT05198063
- Testing
- Recombinant novel coronavirus vaccine (CHO cells)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination
A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination to Evaluate Efficacy, Safety and Immunogenicity
- Trial name
- NCT05911061
- Testing
- High dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell), Low dose of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell), control group
- Volunteers
- 4,950 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
COVID-19
A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above
This is a non-randomized, open-label, externally controlled study to evaluate the safety and immnunogenicity of the Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above with no vaccination…
- Trial name
- COVID-19 (NCT05365724)
- Testing
- Omicron COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- China
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited
COVID-19, Vaccine Adverse Reaction
National Vaccine Adverse Event Reporting Survey and Etiology
If your serious vaccine-induced adverse event has been entered in the CDC Vaccine Adverse Event Reporting System (VAERS) we are interested in enrolling you for this study in order to log your symptoms.
- Conditions
- COVID-19, Vaccine Adverse Reaction, Vaccine Reaction, Vaccine or Biological Substance, Unspecified Causing Adverse Effects in Therapeutic Use
- Trial name
- NVAERS (NCT05095844)
- Testing
- vaccinated
- Where
- United States
- Volunteers
- 100,000 people
- Sponsor
- Neuroganics LLC
Multiple Sclerosis
A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With Ofatumumab
This was a non-interventional, retrospective, observational cohort study involving the abstraction and review of pertinent data from medical records by participating physicians, who completed a customized electronic case report…
- Trial name
- NCT06460324
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Coronavirus Infection
Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers
This is an open label, phase 1 clinical trial of an intra-dermal booster dose of INO-4800 alone or in combination with INO-9112 followed by electroporation (EP) among healthy adults at least 18 years of age, who previously…
- Trial name
- NCT05430958
- Testing
- INO-4800, INO-9112, CELLECTRA® 2000
- Volunteers
- healthy volunteers welcome
- Sponsor
- Inovio Pharmaceuticals
COVID-19
Clinical Trial of Safety and Immunogenicity of Recombinant SARS-CoV-2 S-Trimer Vaccine (CHO Cells) as Booster Vaccination in Populations Aged 18 to 59 Years
Increased immune escape of emerging SARS-CoV-2 variants and waning neutralizing antibody levels over time indicate the importance of COVID-19 vaccine booster dose.
- Trial name
- NCT05716347
- Testing
- the recombinant SARS-CoV-2 S-Trimer vaccine/inactivated SARS-CoV-2 vaccine
- Where
- China
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Binhui Biopharmaceutical Co., Ltd.
COVID-19
The Phase Ⅱ/Ⅲ Trial of LYB001
The study will be conducted in two phases using a randomized, double-blind, placebo-controlled design. A phase II trial will be initiated to assess the safety of LYB001 as booster shots, and then proceed to a phase III trial to…
- Trial name
- NCT05602558
- Testing
- LYB001
- Volunteers
- 18,000 people, healthy volunteers welcome
- Sponsor
- Yantai Patronus Biotech Co., Ltd.
Covid19
COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA
This is a phase 1b, open-label study in adult healthy subjects. This clinical trial is designed to assess the safety, reactogenicity, and immunogenicity the combination of hAd5-S-Fusion+N-ETSD (Suspension for injection) and…
- Trial name
- NCT04732468
- Testing
- hAd5-S-Fusion+N-ETSD (Suspension for injection), hAd5-SFusion+ N-ETSD (Oral capsule)
- Where
- 2 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- ImmunityBio, Inc.
COVID-19, COVID-19 Vaccines
COVID-19 Quantitative Antibody Titers & Booster Vaccinations
This is an observational study aiming at describing COVID-19 vaccination outcomes among HIV-positive and HIV-negative individuals, using electronic health records to observe their usual clinical care.
- Conditions
- COVID-19, COVID-19 Vaccines, Immunogenicity, Vaccine
- Trial name
- NCT05104359
- Testing
- Observational
- Where
- United States
- Volunteers
- 825 people
- Sponsor
- Epividian
Coronavirus Disease 2019
Clinical Study on the Immune Program of Recombinant Novel Coronavirus（COVID-19) Vaccine (CHO Cell)
Popular topic：Clinical study on the immune program of recombinant Novel Coronavirus (COVID-19) vaccine (CHO cell). Research purpose:Main purpose: To evaluate the immunogenicity of recombinant novel coronavirus vaccine (CHO cells)…
- Trial name
- NCT05128643
- Testing
- Recombinant novel coronavirus vaccine (CHO cell)
- Where
- China
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
Study on Sequential Immunization of Omicron Inactivated COVID-19 Vaccine and Prototype Inactivated COVID-19 Vaccine in Population Aged 18 Years Old and Above
This is a randomized, double blind, positive controlled study to evaluate the safety and immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in population aged 18 years old and above who have been vaccinated with…
- Trial name
- COVID-19 (NCT05374954)
- Testing
- Omicron COVID-19 Vaccine (Vero Cell), Inactivated, COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- 10 sites in China
- Volunteers
- 4,200 people, healthy volunteers welcome
- Sponsor
- China National Biotec Group Company Limited